Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Xu, Yajing  [Clear All Filters]
2013
Chen Y, Xu Y, Fu G, Liu Y, Peng J, Fu B, Yuan X, Xin H, Zhu Y, He Q, et al. Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia. Chin J Cancer Res. 2013;25(4):389-96.
2020
Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020.
2022
Liu W, Ji J, Zou D, Cao Y, Xu Y, Zhou J, Gao S, Wang F, Chen W, Du J, et al. Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China. Bone Marrow Transplant. 2022.
2023
Liu E, Fang P, Xin H, Li S, Liu Y, Xu Y, Chen Y. Efficacy and safety of avatrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: A real-world data evaluation on 14 cases. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48(3):376-385.
Shao R, Zhang Y, He J, Huang F, Fan Z, Yang K, Xu Y, Xu N, Luo Y, Deng L, et al. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023;8(1):348.
Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, Chi P, Xu Y, Xu N, Deng L, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023.